Clinical trialNCT05415137CompletedPhase 3Interventional

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

SponsoraTyr Pharma, Inc.Enrollment268Pulmonary Sarcoidosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Lisa Carey
aTyr Pharma, Inc.
Study DirectorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

91 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil

Atyr Investigative Site
Salvador, Estado de Bahia, Brazil
Atyr Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Atyr Investigative Site
São Bernardo do Campo, Brazil
Atyr Investigative Site
São Paulo, Brazil
Atyr Investigative Site
São Paulo, Brazil

France

Atyr Investigative Site
Bobigny, France
Atyr Investigative Site
La Tronche, France
Atyr Investigative Site
Montpellier, France
Atyr Investigative Site
Paris, France
Atyr Investigative Site
Toulouse, France

Germany

Atyr Investigative Site
Essen, Germany
Atyr Investigative Site
Freiburg im Breisgau, Germany
Atyr Investigative Site
Hanover, Germany
Atyr Investigative Site
Heidelberg, Germany

Italy

Atyr Investigative Site
Catania, Italy
Atyr Investigative Site
Florence, Italy
Atyr Investigative Site
Forlì, Italy
Atyr Investigative Site
Milan, Italy
Atyr Investigative Site
Naples, Italy
Atyr Investigative Site
Padua, Italy
Atyr Investigative Site
Rome, Italy
Atyr Investigative Site
Siena, Italy
Atyr Investigative Site
Trieste, Italy

Japan

Kyorin Investigative Site
Aomori, Japan
Kyorin Investigative Site
Fukuoka, Japan
Kyorin Investigative Site
Fukushima, Japan
Kyorin Investigative Site
Hokkaido, Japan
Kyorin Investigative Site
Hokkaido, Japan
Kyorin Investigative Site
Hyōgo, Japan
Kyorin Investigative Site
Kanagawa, Japan
Kyorin Investigative Site
Kanagawa, Japan
Atyr Investigative Site
Kumamoto, Japan
Kyorin Investigative Site
Miyagi, Japan
Kyorin Investigative Site
Okayama, Japan
Kyorin Investigative Site
Osaka, Japan
Kyorin Investigative Site
Shimane, Japan
Kyorin Investigative Site
Shizuoka, Japan
Kyorin Investigative Site
Tokyo, Japan
Kyorin Investigative Site
Tokyo, Japan

Netherlands

Atyr Investigative Site
Nieuwegein, Netherlands

51 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EfzofitimodPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Sept 2022
Primary completion: 25 Jun 2025
Completion: 14 Jul 2025
Last update posted: 4 Jun 2026
Registered enrollment: 268
Registry id: NCT05415137

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.